

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Responses) | | | | | |
|--|--|--|--|-----------------------|--|
| 1. Name and Address of Reporting Person [*] – Binder Gwendolyn | 2. Date of Event Requiring Statement (Month/Day/Year) 10/24/2019 | 3. Issuer Name and Ticker or Trading Symbol Cabaletta Bio, Inc. [CABA] | | | |
| (Last) (First) (Middle) C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600 | 10/24/2019 | 4. Relationship of Issuer (Check Director | Reporting Person all applicable) | | 5. If Amendment, Date Original Filed(Month/Day/Year) |
| (Street) PHILADELPHIA, PA 19104 | | X Officer (give title below) Other (specify below) EVP, Science & Technology | | cify | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person |
| (City) (State) (Zip) | Table I - Non-Derivative Securities Beneficially Owned | | | | |
| 1.Title of Security 2. Amount of Se (Instr. 4) Beneficially Ow (Instr. 4) (Instr. 4) | | ned | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Natur (Instr. 5 | re of Indirect Beneficial Ownership) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | (Instr. 4) | Expiration Date (Month/Day/Year) | | Securities Underlying Derivative | | Price of Derivative | Form of | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|-----------------------------|-------------------------------------|--------------------|----------------------------------|-------------------------------|------------------------|---|---|
| | | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Direct (D) or Indirect (I) (Instr. 5) | |
| | Stock Option (Right to Buy) | <u>(1)</u> | 10/28/2028 | Common Stock | 210,756 | \$ 1.01 | D | |
| | Stock Option (Right to Buy) | <u>(2)</u> | 08/21/2029 | Common Stock | 66,667 | \$ 9.54 | D | |

Reporting Owners

| | Relationships | | | | | |
|--|---------------|-------------------------------|---------------------------|-------|--|--|
| Reporting Owner Name / Address | Director | Director 10% Owner Officer | | Other | | |
| Binder Gwendolyn C/O CABALETTA BIO, INC. 2929 ARCH STREET, SUITE 600 PHILADELPHIA, PA 19104 | | | EVP, Science & Technology | | | |

Signatures

| /s/ Gwendolyn Binder | 10/24/2019 |
|---------------------------------|------------|
| **Signature of Reporting Person | Date |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This option vests over four years, with 25% vesting on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments (1) thereafter.
- (2) This option vests over four years, with 25% vesting on August 22, 2020, and the remaining shares vesting in 12 equal quarterly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY For Executing Forms 3, 4 and 5

Know all by these presents, that the undersigned hereby constitutes and appoints each of Steven Nichtberger, M.D., Anup Marda, MBA and J. Brian Stalter, J.D., each acting singly, her true and lawful attorney-in-fact from October 24, 2019 to:

(1) Execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of Cabaletta Bio, Inc. (the "Company"), forms and authentication documents for EDGAR Filing Access;

(2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete the execution of any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and the timely filing of such form with the United States Securities and Exchange Commission and any other authority; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully for all intents and purposes as the such attorney-infact might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

By this Power of Attorney, the undersigned further revokes all previous powers of attorney relating to the undersigned's obligations to file Forms 3, 4 and 5 in respect of the Company's securities under Section 16(a) of the Securities Exchange Act of 1934 and related matters.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date first set forth above.

/s/ Gwendolyn Binder Name: Gwendolyn Binder, Ph.D.